Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics Closes $77M Funding Round

NEW YORK (GenomeWeb) – Sophia Genetics said today that it has closed on a $77 million Series E round of venture capital, led by new investor Generation Investment Management, with participation from Idinvest Partners and previous Sophia equity backers Balderton Capital and Alychlo.

Sophia, which now has co-headquarters in Boston and Lausanne, Switzerland, said that it will apply much of the new funding to expand its US presence by growing its workforce and marketing to more American hospitals.

"With Generation’s support, we will enable the more rapid adoption of data-driven medicine technology in healthcare for the benefit of patients worldwide," added Sophia CEO and Founder Jurgi Camblong.

Sophia Genetics last landed new funding in a $30 million Series D round that closed in September 2017. To date, the company has raised $140 in private equity.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.